Psychedelic-Assisted Therapy

Psychedelic-assisted therapy refers to the use of psychedelic substances such as LSD, psilocybin, and MDMA, in a therapeutic context. The goal of psychedelic therapy is to help individuals overcome mental health issues such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).

During a psychedelic therapy session, a trained professional guides the patient through a psychedelic experience, providing support and guidance as needed. The patient is encouraged to explore their thoughts and emotions, with the intention of gaining a deeper understanding of themselves and their mental health issues.

Research has shown that psychedelic therapy can be effective in treating a range of mental health conditions. For example, studies have found that psilocybin can be helpful in reducing anxiety and depression in people with terminal illnesses, while MDMA-assisted therapy has shown promise in treating PTSD.

It is important to note that psychedelic therapy is still an emerging field, and there is much more research that needs to be done before it can be widely adopted as a mainstream treatment option. Additionally, the use of psychedelic substances outside of a therapeutic context can be dangerous and is illegal in many places.

During the ReWild Medicine program sequence, psychedelic-assisted therapy is conducted using ketamine. Ketamine is not FDA approved for mental health indications. The ReWild Medicine program involves off-label use of intramuscular ketamine injections coupled with psychotherapy known as ketamine-assisted psychotherapy. The clinical experience to date with ketamine-assisted therapy, indicates that the best outcomes for conditions like depression and addiction occur with multiple sessions (typically at least 4-6 sessions) with intervening integration/counseling sessions.

Learn more at